camurus semaglutide FDA accepts CAM2029 NDA resubmission for Acromegaly, sets December 2026 PDUFA Date – Camurus.⁠ ⁠ Click the link in our bio to read the full story on our website.⁠ ⁠ #medicalnews #medicine # Camurus CAM2029 NDA Resubmission Accepted

Sensitivity analyses (leave-one-out method) and publication bias assessments (Eggers regression) were not performed because the number of studies did not meet minimum thresholds (five for sensitivity, ten for publication bias)

It's often overlooked but crucial for gut health and feeling full

One of the less common but notable side effects is the development of a rash

For patients I see in clinic, retatrutide may potentially be a highly impactful future tool to treat their obesity and transform their health trajectory. (You can now subscribe to our Economic Times WhatsApp channel) (Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.) Subscribe to The Economic Times Prime and read the ET ePaper online

Apoptosis in Autoimmune Diabetes: The Fate of Beta-Cells in the Cleft Between Life and Death

What began as a diabetes treatment story has rapidly evolved into a broader metabolic health transformation